AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., a near-commercial biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other diseases, announced the closing of its $120 million Series C financing.

The financing was led by a leading strategic investor, with participation from new investor RA Capital Management, L.P., alongside continued support from AusperBio's existing investors, including HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. With the completion of the Series C, AusperBio has raised $360 million since 2024, reflecting strong and sustained investor confidence in the potential of the Company's lead programs and differentiated oligonucleotide platforms.